Akcea Therapeutics reports Q2 EPS (72c), consensus ($1.24)
Reports Q2 revenue $18.3M, consensus $12.56M. "This is an incredibly exciting time for Akcea with TEGSEDI now approved in Europe and upcoming PDUFA dates in the US for WAYLIVRAand TEGSEDI. We are ready to launch TEGSEDI first in Germany post the summer holidays, and in the US, we are prepared to launch both products quickly upon approval. We are poised to deliver these drugs to two underserved, rare disease patient communities in our three initial key regions. We've also accelerated global access to TEGSEDI and WAYLIVRA in Latin America through our partnership with PTC Therapeutics," said Paula Soteropoulos, chief executive officer of Akcea. "In addition, with the upcoming top line results from the AKCEA-APO(a)-LRx Phase 2 study, we have the potential to make a significant step forward for patients with cardiovascular disease caused by elevated levels of lipoprotein a, or Lp(a). With the largest efficacy, safety and treatment duration database to date, these results could be a game changer for the ligand conjugated antisense, or LICA, technology platform and we look forward to sharing them later this year."